Key result
C-reactive protein levels ≥10 mg/L indicate higher risk for death and myocardial infarction in acute coronary syndromes, while ≥3 mg/L identifies intermediate risk and high recurrent event rates.
Why the study?
Does evaluation of C-reactive protein (CRP) levels at time of admission predict risk for death and myocardial infarction in patients with acute coronary syndromes?
Does evaluation of C-reactive protein (CRP) levels at time of admission predict risk for death and myocardial infarction in patients with acute coronary syndromes?
CRP levels at admission provide valuable prognostic information for risk stratification in patients with acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
CRP thresholds may refine ACS risk stratification; hypothesis-generating and requires prospective validation before practice change.
Abbate et al. (2003) conducted a review in Acute coronary syndromes. C-reactive protein (CRP) was evaluated on Death, myocardial infarction, and recurrent events. C-reactive protein levels ≥10 mg/L indicate higher risk for death and myocardial infarction in acute coronary syndromes, while ≥3 mg/L identifies intermediate risk and high recurrent event rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: